On May 1, 2025, The U.S. Department of Health and Human Services (HHS) released a 409 page document titled “Treatment for Pediatric Gender Dysphoria – Review of Evidence and Best Practices.” On reviewing the document, I was pleased that the findings confirmed what the CASS Report from the United Kingdom pointed out last year leading to a retraction of some aggressive “gender affirming” treatments in parts of Europe. There is scant evidence backing what the World Professional Association of Transgender Health (WPATH) has been pushing as standard of care for gender dysphoria treatment in children (age < 18 years old). There is very little out there in the scientific literature universe as to the long term effects of suppressing puberty with puberty blockers or giving cross sex hormones for the development of secondary sexual characteristics not aligned with one’s biological sex in the pediatric population. Back in the day, medical school for me was 1986-1990 and residency training 1990-1994, there were three groups one treated where extreme caution was exercised – children, pregnant women, and the elderly (age > 65). It is shocking to me that over the span of 35 years, professional medical organizations have been co-opted by identity politics and the pharmaceutical industry. The American Academy of Pediatrics, the American Academy of Family Physicians, the Endocrine Society, and many other medical organizations are howling that the report advocates “conversion therapy.”
Treatment for Pediatric Gender Dysphoria
HHS Releases Damning Report on ‘Gender-Affirming Care’
doctordeplorablemf